Klotho Neurosciences (KLTO)announced that the FDA has granted Orphan Drug Designation to the company’s novel secreted-Klotho promoter, gene and delivery system for the treatment of ALS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences amyotrophic lateral sclerosis treatment gets orphan status
- 3 Penny Stocks to Watch Now, 7/1/25
- Klotho Neurosciences Begins Manufacturing Gene Therapy for ALS
- Klotho Neurosciences moves forward with KLTO-202 manufacturing and development
- Klotho Neurosciences, ORCLS announce plan to study Blue Zone